Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.
- NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_assertion description "[Encouraging response rates of about 50% in myelodysplasia with 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine or DAC) have resulted in a number of phase III studies being initiated in this disorder.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.
- NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_assertion evidence source_evidence_literature NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.
- NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_assertion SIO_000772 16210092 NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.
- NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_assertion wasDerivedFrom befree-20150227 NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.
- NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_assertion wasGeneratedBy ECO_0000203 NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.
- befree-20150227 importedOn "2015-02-27" NP217971.RAHC6bPXH7pdwzbgUXu-kZ5k7cfsWKUuT95fdQOxvGy2M130_provenance.